Title: Author response: Natural history and survival in stage 1 Val30Met transthyretin familial amyloid polyneuropathy
Abstract: In our study,1 we evaluated all-cause mortality and a 76% survival rate at 10 years among Val30Met liver transplant (LTx)-treated patients (n = 957) was found. Notably, a previous study of Japanese patients with transthyretin-associated familial amyloid polyneuropathy Val30Met reported a 100% survival rate at 10 years among LTx-treated patients (n = 37).2 In the Yamashita et al.
Publication Year: 2019
Publication Date: 2019-07-30
Language: en
Type: letter
Indexed In: ['crossref', 'pubmed']
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot